To synthesize the available evidence on the effect of electromyographic biofeedback in the treatment of quadriceps strength following ACL surgery.
Systematic review with meta-analysis.
PubMed, EMBASE, CENTRAL and Epistemonikos were searched.
Randomized clinical trials with patients undergoing ACL reconstruction surgery comparing biofeedback with a standard rehabilitation control group.
Two authors selected articles and performed data extraction. The analysed outcomes were strength, function, pain, knee extension and balance. The risk of bias of individual studies was assessed using the Cochrane Risk of Bias Tool. Results were combined through random-effects meta-analysis, reporting mean differences.
Eight articles were included in the qualitative analysis, and four articles were included in the quantitative analysis. The interventions lasted between 4 and 12 weeks. Three studies evaluated the effect of biofeedback on quadriceps strength; of these, two studies showed a significant difference in favour of the biofeedback group. In addition, biofeedback was found to improve knee extension [standardized mean difference - 1.3, 95% confidence interval (CI) - 1.74 to -0.86] and balance (one study). There was no significant difference in Lysholm score (mean difference -6.21, 95% CI -17.51 to 5.08; I2 =59%) or pain between the biofeedback group and the control group.
Electromyographic biofeedback in knee rehabilitation could be useful following ACL reconstruction surgery.
SYSTEMATIC REVIEW REGISTRATION NUMBER: PROSPERO (CRD42020193768).
目的:综合关于肌电生物反馈在ACL术后股四头肌力量治疗中的作用的现有证据。
方法:系统评价与荟萃分析。
方法:PubMed,EMBASE,搜索了CENTRAL和Epidemonikos。
方法:对接受ACL重建手术的患者进行随机临床试验,比较生物反馈和标准康复对照组。
方法:两位作者选择了文章并进行了数据提取。分析的结果是力量,函数,疼痛,膝盖伸展和平衡。使用Cochrane偏差风险工具评估个体研究的偏差风险。结果通过随机效应荟萃分析相结合,报告平均差异。
结果:共8篇纳入定性分析,并对4篇文献进行了定量分析。干预持续了4到12周。三项研究评估了生物反馈对股四头肌力量的影响;其中,两项研究表明,对生物反馈组的支持存在显着差异。此外,发现生物反馈可改善膝关节伸展[标准化平均差-1.3,95%置信区间(CI)-1.74~-0.86]和平衡(一项研究).生物反馈组与对照组在Lysholm评分(平均差-6.21,95%CI-17.51至5.08;I2=59%)或疼痛方面无显著差异。
结论:在ACL重建手术后,肌电生物反馈在膝关节康复中可能是有用的。
结论:系统审查登记号:PROSPERO(CRD42020193768)。